OmniAb, Inc. (NASDAQ:OABI) Shares Sold by Chicago Capital LLC

Chicago Capital LLC lessened its position in shares of OmniAb, Inc. (NASDAQ:OABI) by 5.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,975,451 shares of the company’s stock after selling 187,104 shares during the quarter. Chicago Capital LLC owned approximately 2.11% of OmniAb worth $10,533,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in OABI. Dimensional Fund Advisors LP raised its stake in OmniAb by 6.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock valued at $11,296,000 after purchasing an additional 194,835 shares during the last quarter. Sei Investments Co. increased its stake in shares of OmniAb by 11.0% during the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock valued at $109,000 after acquiring an additional 2,888 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of OmniAb during the 2nd quarter valued at about $449,000. The Manufacturers Life Insurance Company acquired a new position in shares of OmniAb during the 2nd quarter valued at about $147,000. Finally, SG Americas Securities LLC grew its holdings in shares of OmniAb by 105.6% during the 3rd quarter. SG Americas Securities LLC now owns 34,858 shares of the company’s stock worth $147,000 after purchasing an additional 17,901 shares during the period. Institutional investors and hedge funds own 72.08% of the company’s stock.

Insiders Place Their Bets

In other OmniAb news, CFO Kurt A. Gustafson sold 15,526 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $50,304.24. Following the completion of the transaction, the chief financial officer now owns 212,720 shares in the company, valued at $689,212.80. This represents a 6.80 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Charles S. Berkman sold 25,489 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total value of $82,584.36. Following the transaction, the insider now owns 343,190 shares of the company’s stock, valued at approximately $1,111,935.60. This trade represents a 6.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,826 shares of company stock worth $268,356 in the last 90 days. 8.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

OABI has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of OmniAb in a report on Thursday, November 14th. Benchmark reiterated a “buy” rating and set a $8.00 target price on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Stock Up 0.3 %

NASDAQ OABI opened at $3.22 on Monday. The stock has a market cap of $454.73 million, a PE ratio of -5.19 and a beta of -0.10. OmniAb, Inc. has a fifty-two week low of $3.10 and a fifty-two week high of $6.55. The business has a 50 day moving average price of $3.58 and a two-hundred day moving average price of $4.00.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.